07/02/2021 RMMS is once again honoredto have been recognized as a leading intellectual property firm in the 2021 edition ofIAM Patent 1000: The World’s Leading Patent Professionals, a guide to the top intellectual property law practitioners around the globe. The firm retainedits strong ranking in the ‘Silver’ band for Intellectual Property Litigation. Regarding the firm’s work, IAM notes:
For generic drug manufacturers, Rakoczy Molino Mazzochi Siwik is a godsend; the prolific life sciences patent litigation boutique has handled several hundred Hatch-Waxman and Biologics Price Competition and Innovation Act suits since opening its doors in 2004, giving it a major advantage and a rich playbook to utilise for the next few hundred cases.
RMMS is also pleased that five of our partners were recognized for their individual accomplishments. Lara FitzSimmons makes her debut in the IAM Patent 1000 as a leading regulatory counselling and deal lawyer, with IAM calling her ‘a vital cog in the firm’s litigation efforts thanks to her for her facility for settlement negotiation.’ Ms. FitzSimmons joins William Rakoczy, Paul Molino, Deanne Mazzochi, and Eric Hunt in the individual rankings.
The https://www.iam-media.com/directories/patent1000/rankings/united-states-illinois identifies the top patent professionals and firms in key jurisdictions around the globe. The guide is compiled after an extensive research process. Individuals qualify for a listing in theIAM Patent 1000when they receive sufficient positive feedback from peers and clients with knowledge of their practice and the market within which they operate. Firms qualify for a listing on the basis of their depth of knowledge, market presence, and the level of work on which they are typically engaged, as well as positive peer and client feedback.
About RMMS Headquartered in Chicago,RMMS is a full-service litigation and intellectual property law firm with over 30 attorneys devoted exclusively to the life sciences industry, including specialty practice in the field of patent and regulatory counseling and litigation under theHatch-Waxman Act, the Medicare Prescription Drug, Improvement, and Modernization Act (MMA), and the Biologics Price Competition and Innovation Act (BPCIA).